Loading video...

Video Failed to Load

Go Home

Pfizer is advancing obesity science. New Phase 2b data for our investigational GLP‑1 RA peptide show robust efficacy and favourable GI tolerability across weekly and monthly dosing, supporting our extensive pivotal program. Learn more: [link] #ADASciSessions #Obesity #GLP1 #ClinicalTrials #Innovation #Healthcare

11,700 views • 3 months ago •via X (Twitter)

0 Comments

No comments available

Comments from the original post will appear here

Related Videos